A drug called NVG-291, developed by NervGen Pharma, is generating serious momentum in the spinal cord injury field — and for good reason. In November 2025, the company released expanded data from its CONNECT SCI Study showing what it described as “unprecedented durable improvement in function, independence, and quality of life” in people living with chronic spinal cord injury. Patients receiving NVG-291 showed a three-fold increase in motor connectivity strength compared to placebo. To put this in perspective, there are currently zero FDA-approved pharmacologic treatments for spinal cord injury. None. NVG-291 could become the first.
But NVG-291 is not the only therapy drawing attention. A Northwestern University technology dubbed “dancing molecules” received FDA Orphan Drug Designation in July 2025 and is on track for human trials in late 2026. Riluzole, a drug already used for ALS, is being studied for acute spinal cord injury recovery. Researchers at UC San Diego identified a compound called thiorphan through bioinformatics that produced a 50 percent increase in recovery of hand function in animal models. And XellSmart Biopharmaceutical received approval from both China’s NMPA and the U.S. FDA to begin Phase I clinical trials for an iPSC stem cell therapy. This article covers all of these developments, what they mean for patients and caregivers, and the honest limitations that come with experimental treatments still working through the pipeline.
Table of Contents
- Why Is NVG-291 Getting So Much Attention as a Spinal Cord Injury Drug in 2025?
- Dancing Molecules and Nanofiber Therapy — A Different Approach to Spinal Repair
- Riluzole — Can an Existing ALS Drug Help After Spinal Cord Injury?
- Thiorphan and Stem Cell Combinations — What the Research Actually Shows
- Stem Cell Therapies and the Regulatory Landscape
- Non-Drug Options — The ARC-EX System for Chronic SCI
- What the Next Two Years Could Look Like for SCI Treatment
- Conclusion
- Frequently Asked Questions
Why Is NVG-291 Getting So Much Attention as a Spinal Cord Injury Drug in 2025?
NVG-291 stands out because it is not simply managing symptoms or slowing decline — it appears to facilitate actual nervous system repair. In June 2025, NervGen Pharma reported positive topline data from the chronic cohort of its Phase 1b/2a CONNECT SCI Study, showing that NVG-291 improved motor connectivity in participants with chronic cervical spinal cord injury. The three-fold increase in motor connectivity strength versus placebo is a striking number in a field where incremental gains have historically been the norm. The FDA has granted NVG-291 Fast Track designation, and the European Medicines Agency awarded it Orphan Designation, both signals that regulators see enough promise to expedite the review process. What makes this particularly significant for dementia care professionals and brain health advocates is the underlying mechanism. NVG-291 works on neural repair pathways that have relevance beyond spinal cord injury.
The idea that a pharmacologic agent can help the nervous system rebuild connections in chronic injury — not just acute — challenges long-held assumptions about the limits of neurological recovery. For families caring for someone with both cognitive decline and mobility impairment from spinal injury, a treatment that restores even partial motor function could dramatically change daily caregiving demands. However, it is important to be realistic about where NVG-291 stands. The data comes from a Phase 1b/2a trial, which is still early-stage. The study populations are small. The FDA has confirmed that multiple regulatory routes are available to support approval, but approval itself has not happened. Patients and families should track this closely without assuming a timeline for availability.
Dancing Molecules and Nanofiber Therapy — A Different Approach to Spinal Repair
Not every promising SCI therapy works the same way. The “dancing molecules” technology developed by the Stupp Lab at Northwestern University takes a fundamentally different approach from NVG-291. Rather than a traditional drug compound, this therapy uses nanofibers that contain bioactive signals designed to trigger regenerative pathways. In animal studies, these nanofibers enabled motor neurons from the brain to regrow past the injury site and reconnect to the lower spinal cord — essentially reversing paralysis at the cellular level. In July 2025, the therapy received FDA Orphan Drug Designation for acute spinal cord injury. The company commercializing the technology, Amphix Bio, is targeting late 2026 for first human clinical trials and is currently completing safety studies and preparing an Investigational New Drug application to the FDA.
The distinction between this approach and NVG-291 matters: the dancing molecules therapy is aimed at acute injury, meaning it would need to be administered relatively soon after the spinal cord is damaged. NVG-291, by contrast, has shown results in chronic injury — people who were injured months or years ago. This is a critical limitation for caregivers to understand. If someone you care for sustained a spinal cord injury years ago, a therapy designed for the acute window may not apply to their situation. The dancing molecules approach holds enormous promise, but it is further from the clinic than NVG-291, and its application may be narrower. That said, if proven effective, it could be transformative for preventing long-term disability in the immediate aftermath of traumatic injury.
Riluzole — Can an Existing ALS Drug Help After Spinal Cord Injury?
Drug repurposing is one of the fastest routes from the lab to the patient, because a repurposed drug already has an established safety profile in humans. Riluzole is a case in point. Already approved and commonly used to treat amyotrophic lateral sclerosis and other motor neuron diseases, riluzole is now being studied for its potential to assist in spinal cord injury recovery. Research published in September 2025 suggests that riluzole may offer benefits if taken within 12 hours of injury. That 12-hour window is both the promise and the challenge.
For riluzole to work in this context, it would need to be administered almost immediately after injury, which means emergency departments and trauma centers would need to have it on hand and protocols in place. For families dealing with degenerative neurological conditions like dementia, the relevance is more indirect — riluzole’s mechanism of action involves protecting neurons from excitotoxicity, a process that also plays a role in neurodegenerative disease. The research community is watching closely to see whether these neuroprotective properties can be leveraged across conditions. One practical advantage of riluzole is that doctors already know its side effect profile, drug interactions, and dosing parameters from years of use in ALS patients. If clinical trials confirm its efficacy in acute SCI, it could move through regulatory approval faster than a completely novel compound. But the narrow treatment window means it is not a solution for the millions of people already living with chronic spinal cord injuries.
Thiorphan and Stem Cell Combinations — What the Research Actually Shows
Researchers at UC San Diego took a novel approach to drug discovery for spinal cord injury by using bioinformatics to identify existing compounds with regenerative potential. The standout candidate was thiorphan, a drug previously tested in humans for non-neurological conditions. In animal studies, rats treated with thiorphan alone showed a 50 percent increase in recovery of hand function after spinal cord injury compared to untreated animals. When thiorphan was combined with a neural stem cell implant, an additional 50 percent improvement in hand function was observed. The combination approach is worth paying attention to. Single therapies for complex neurological injuries have historically produced modest results. The thiorphan data suggests that pairing a pharmacologic agent with cellular therapy may produce additive or even synergistic benefits.
Researchers also tested thiorphan successfully in adult human brain cells, showing increased neurite outgrowth — a key metric for neural regeneration. This has implications well beyond spinal cord injury, potentially extending to traumatic brain injury and neurodegenerative conditions. The tradeoff is time and certainty. Thiorphan’s SCI results come from animal models, not human clinical trials. The leap from rats to humans is significant and often disappointing. Many compounds that show dramatic results in rodents fail to replicate those outcomes in people. Families should view this as genuinely exciting early-stage science, not as a treatment that will be available next year. The combination with stem cells also adds regulatory complexity, as the FDA would likely need to evaluate both components.
Stem Cell Therapies and the Regulatory Landscape
XellSmart Biopharmaceutical reached a notable milestone in May 2025 when it received approval from both China’s NMPA and the U.S. FDA to begin Phase I clinical trials for an iPSC therapy for spinal cord injury. iPSC stands for induced pluripotent stem cell — these are adult cells that have been reprogrammed back to an embryonic-like state, allowing them to develop into virtually any cell type. The dual-country approval is unusual and suggests the company is pursuing a global development strategy. Stem cell therapies for neurological conditions have been discussed for decades, and that long history comes with an important warning. The field has been plagued by unregulated clinics around the world offering unproven stem cell treatments at enormous cost, sometimes causing serious harm.
Any legitimate stem cell therapy for spinal cord injury will go through formal clinical trials with regulatory oversight. Families should be deeply skeptical of any clinic currently offering stem cell “cures” for SCI outside of registered clinical trials. The ClinicalTrials.gov database is the best place to verify whether a trial is legitimate. The iPSC approach has a theoretical advantage over other stem cell methods because the cells can be derived from the patient’s own tissue, potentially reducing immune rejection. But Phase I trials are primarily about safety, not efficacy. Even with FDA approval to begin trials, it will be years before we know whether XellSmart’s therapy actually works.
Non-Drug Options — The ARC-EX System for Chronic SCI
While pharmacologic treatments remain in development, one non-drug technology has already crossed the regulatory finish line. The ARC-EX System from ONWARD Medical is the first and only FDA-approved non-invasive technology clinically proven to improve hand strength and sensation for individuals with chronic spinal cord injury. It works by delivering programmed electrical stimulation through the skin to the spinal cord via electrodes placed on the back of the neck.
For caregivers managing someone with both spinal cord injury and cognitive decline, the ARC-EX system represents a fundamentally different category of intervention — it is available now, not years away. It does not repair damaged tissue or regrow neurons, but it can meaningfully improve function in daily life. This is worth discussing with a rehabilitation specialist, particularly for individuals whose chronic SCI has been treated as a static, unchangeable condition. The device is not a cure, but it is the only approved option that currently exists while the pharmaceutical pipeline matures.
What the Next Two Years Could Look Like for SCI Treatment
The period from 2026 through 2028 may be the most consequential stretch in the history of spinal cord injury treatment. NVG-291 is the furthest along in clinical development and could become the first FDA-approved pharmacologic treatment for SCI. If NervGen Pharma moves into Phase 3 trials successfully, a regulatory submission could follow within a few years. The dancing molecules therapy from Amphix Bio is expected to enter human trials in late 2026, which will generate the first clinical data on whether nanofiber-based neural regeneration works in people.
For the brain health and dementia care community, these developments matter beyond their direct application to spinal cord injury. The mechanisms being studied — neural repair, connectivity restoration, neuroprotection, stem cell integration — are the same mechanisms that researchers hope to harness for Alzheimer’s disease, Parkinson’s disease, and other forms of neurodegeneration. A breakthrough in SCI could accelerate progress across the entire field of neurological medicine. Families should stay informed, remain cautious about unproven treatments, and talk with their medical teams about whether any registered clinical trials might be appropriate for their loved ones.
Conclusion
The spinal cord injury treatment landscape in 2025 looks radically different from even a few years ago. NVG-291 has demonstrated measurable motor connectivity improvements in chronic SCI patients and holds Fast Track designation from the FDA. The dancing molecules nanofiber therapy has received Orphan Drug Designation and is heading toward human trials. Riluzole offers a repurposing pathway for acute injuries. Thiorphan and stem cell combinations are producing compelling animal data.
And the ARC-EX system is already available as the first FDA-approved non-invasive device for chronic SCI. None of these therapies should be treated as guaranteed solutions. Clinical trials fail more often than they succeed, regulatory timelines shift, and early-stage data does not always hold up at scale. But the sheer number of serious, well-funded approaches moving through the pipeline at the same time is unprecedented for a condition that has had zero approved pharmacologic treatments. For caregivers, patients, and families navigating neurological injury alongside conditions like dementia, the most practical step right now is to stay connected with rehabilitation specialists, monitor ClinicalTrials.gov for relevant studies, and approach any treatment claims outside of formal clinical trials with healthy skepticism.
Frequently Asked Questions
Are there any FDA-approved drugs for spinal cord injury right now?
No. As of late 2025, there are zero FDA-approved pharmacologic treatments for spinal cord injury. NVG-291 is the furthest along in development and could potentially become the first, but it has not yet received approval.
What is NVG-291 and how does it work?
NVG-291 is an experimental drug developed by NervGen Pharma that facilitates nervous system repair. In clinical trials, it produced a three-fold increase in motor connectivity strength in patients with chronic cervical spinal cord injury compared to placebo. It has received FDA Fast Track designation and EMA Orphan Designation.
Can riluzole help someone who was injured years ago?
Current research suggests riluzole may only offer benefits if administered within 12 hours of a spinal cord injury. It does not appear to be effective for chronic, long-standing injuries. Its potential use is limited to the acute phase immediately following trauma.
What is the “dancing molecules” therapy?
Developed at Northwestern University’s Stupp Lab, it uses nanofibers containing bioactive signals that trigger regenerative pathways. In animal studies, motor neurons regrew past the injury site and reconnected to the lower spinal cord. Human trials, led by Amphix Bio, are expected to begin in late 2026.
Should I consider stem cell treatments being offered at private clinics?
Extreme caution is warranted. Legitimate stem cell therapies go through formal, regulated clinical trials. Many private clinics worldwide offer unproven stem cell treatments at high cost, and some have caused serious harm. Always verify through ClinicalTrials.gov that any trial is registered and regulated before participating.
Is there anything available right now for chronic spinal cord injury?
The ARC-EX System from ONWARD Medical is the first and only FDA-approved non-invasive technology clinically proven to improve hand strength and sensation for individuals with chronic SCI. It uses electrical stimulation delivered through electrodes on the back of the neck. Speak with a rehabilitation specialist about whether it may be appropriate.
